Hydroxamic Acid Hybrids for Lung Cancer Therapy

IF 3.6 3区 医学 Q2 CHEMISTRY, MEDICINAL
Donghong Wang, Yanjing Cheng, Aimei Liu, Yafei Zhuang
{"title":"Hydroxamic Acid Hybrids for Lung Cancer Therapy","authors":"Donghong Wang,&nbsp;Yanjing Cheng,&nbsp;Aimei Liu,&nbsp;Yafei Zhuang","doi":"10.1002/ardp.70067","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Lung cancer is one of the most common and deadly cancers across the world nowadays, and the morbidity and mortality of lung cancer will continue to increase for a long period. Chemotherapy, which can kill cancer cells, shrink tumors, and improve patient survival and quality of life, plays a crucial role in lung cancer therapy. However, chemotherapy has several disadvantages, mainly manifested in severe side effects, limited efficacy, and the tendency to develop drug resistance. Histone deacetylase (HDAC) inhibitors, which work by inhibiting the activity of HDACs, can help to re-express tumor-suppressor genes that have been silenced due to epigenetic changes, thus inhibiting the growth and proliferation of lung cancer cells. Hydroxamic acid hybrids as potent HDAC inhibitors exhibited robust in vitro and in vivo efficacy against drug-sensitive and drug-resistant lung cancers, representing crucial templates in creating innovative anti-lung cancer agents. This article will introduce the latest research progress on hydroxamic acid hybrids with anti-lung cancer activity developed since 2020. The structure–activity relationships will be summarized, and the mechanisms of action will be discussed to provide references for future research.</p></div>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 8","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archiv der Pharmazie","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ardp.70067","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Lung cancer is one of the most common and deadly cancers across the world nowadays, and the morbidity and mortality of lung cancer will continue to increase for a long period. Chemotherapy, which can kill cancer cells, shrink tumors, and improve patient survival and quality of life, plays a crucial role in lung cancer therapy. However, chemotherapy has several disadvantages, mainly manifested in severe side effects, limited efficacy, and the tendency to develop drug resistance. Histone deacetylase (HDAC) inhibitors, which work by inhibiting the activity of HDACs, can help to re-express tumor-suppressor genes that have been silenced due to epigenetic changes, thus inhibiting the growth and proliferation of lung cancer cells. Hydroxamic acid hybrids as potent HDAC inhibitors exhibited robust in vitro and in vivo efficacy against drug-sensitive and drug-resistant lung cancers, representing crucial templates in creating innovative anti-lung cancer agents. This article will introduce the latest research progress on hydroxamic acid hybrids with anti-lung cancer activity developed since 2020. The structure–activity relationships will be summarized, and the mechanisms of action will be discussed to provide references for future research.

羟基肟酸复合物用于肺癌治疗
肺癌是当今世界上最常见和最致命的癌症之一,肺癌的发病率和死亡率将在很长一段时间内持续上升。化疗可以杀死癌细胞,缩小肿瘤,提高患者的生存和生活质量,在肺癌治疗中起着至关重要的作用。然而,化疗也有一些缺点,主要表现在副作用严重,疗效有限,容易产生耐药性。组蛋白去乙酰化酶(Histone deacetylase, HDAC)抑制剂通过抑制HDAC的活性起作用,可以帮助因表观遗传变化而沉默的肿瘤抑制基因重新表达,从而抑制肺癌细胞的生长和增殖。羟肟酸杂合体作为有效的HDAC抑制剂,在体外和体内对药物敏感和耐药的肺癌表现出强大的疗效,代表了创造创新抗肺癌药物的关键模板。本文将介绍2020年以来具有抗肺癌活性的羟肟酸杂合体的最新研究进展。总结其构效关系,探讨其作用机制,为今后的研究提供参考。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Archiv der Pharmazie
Archiv der Pharmazie 医学-化学综合
CiteScore
7.90
自引率
5.90%
发文量
176
审稿时长
3.0 months
期刊介绍: Archiv der Pharmazie - Chemistry in Life Sciences is an international journal devoted to research and development in all fields of pharmaceutical and medicinal chemistry. Emphasis is put on papers combining synthetic organic chemistry, structural biology, molecular modelling, bioorganic chemistry, natural products chemistry, biochemistry or analytical methods with pharmaceutical or medicinal aspects such as biological activity. The focus of this journal is put on original research papers, but other scientifically valuable contributions (e.g. reviews, minireviews, highlights, symposia contributions, discussions, and essays) are also welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信